Replies to post #3549 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Is it possible that Atryn could receive FDA approval for DIC/sepsis concurrent with HD or earlier?<

That’s not possible because the DIC program will not even have started phase-3 when the BLA for the HD indication is being reviewed by the FDA.

>What if the Leo DIC studies are highly compelling?<

Approval for HD could allow for some off-label use of Atryn in DIC if the phase-2 data are extremely compelling.

>What else is there besides Xigris?<

Basically nothing. Regards, Dew